|
A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM). |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; Janssen Research & Development |
Research Funding - Agenus; Bristol-Myers Squibb; Janssen Research & Development |
|
|
Travel, Accommodations, Expenses - Amgen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Celgene; Janssen; Prothena; Seagen; Takeda |
Research Funding - Celgene (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
Stock and Other Ownership Interests - Agios; Celgene; Juno Therapeutics |
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Roche; Takeda |
|
Travel, Accommodations, Expenses - Amgen; Celgene; Novartis |
|
|
Research Funding - Celgene (Inst) |